General Information of Drug (ID:
DR3373) |
Drug Name |
VX-509
|
Synonyms |
Decernotinib; Adelatinib; 944842-54-0; VX-509; UNII-MZK2GP0RHK; Decernotinib(VX-509); VX509; MZK2GP0RHK; VRT-831509; VX 509; (2r)-2-Methyl-2-[[2-(1h-Pyrrolo[2,3-B]pyridin-3-Yl)pyrimidin-4-Yl]amino]-N-[2,2,2-Tris(Fluoranyl)ethyl]butanamide; (R)-2-((2-(1H-Pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide; Decernotinib [USAN:INN]; VRT 831509; Decernotinib,VX-509; Decernotinib (USAN/INN); Decernotinib (VX-509); VX-509 (Decernotinib); SCHEMBL2630387; GTPL8309; CHEMBL3039513; KS-00001CYK
|
Indication |
Rheumatoid arthritis
[ICD11: FA20]
|
Phase 2/3
|
[1]
|
Structure |
|
|
3D MOL is unavailable
|
2D MOL
|
Pharmaceutical Properties |
Molecular Weight |
392.4 |
Topological Polar Surface Area |
95.6 |
Heavy Atom Count |
28 |
Rotatable Bond Count |
6 |
Hydrogen Bond Donor Count |
3 |
Hydrogen Bond Acceptor Count |
8 |
Cross-matching ID |
- PubChem CID
- 59422203
- CAS Number
-
- TTD Drug ID
- D04QWQ
- Formula
- C18H19F3N6O
- Canonical SMILES
- CC[C@](C)(C(=O)NCC(F)(F)F)NC1=NC(=NC=C1)C2=CNC3=C2C=CC=N3
- InChI
- InChI=1S/C18H19F3N6O/c1-3-17(2,16(28)25-10-18(19,20)21)27-13-6-8-23-15(26-13)12-9-24-14-11(12)5-4-7-22-14/h4-9H,3,10H2,1-2H3,(H,22,24)(H,25,28)(H,23,26,27)/t17-/m1/s1
- InChIKey
- ASUGUQWIHMTFJL-QGZVFWFLSA-N
|
|
|
|
|
|
|
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.